The Current Ratio as of November 2024 (TTM) for Innoviva, Inc. (INVA) is 1.79

According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.79. This represents a change of -78.90% compared to the average of 8.48 of the last 4 quarters.

Innoviva, Inc. (INVA) Historical Current Ratio (quarterly & annually)

How has INVA Current Ratio performed in the past?

The mean historical Current Ratio of Innoviva, Inc. over the last ten years is 31.89. The current 1.79 Current Ratio has changed 461.54% with respect to the historical average. Over the past ten years (40 quarters), INVA's Current Ratio was at its highest in in the March 2020 quarter at 166.87. The Current Ratio was at its lowest in in the September 2024 quarter at 1.79.

Innoviva, Inc. (INVA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Innoviva, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Innoviva, Inc. (INVA) Average Current Ratio

How has INVA Current Ratio performed in the past?

The current Current Ratio of Innoviva, Inc. (INVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Innoviva, Inc. (INVA) Current Ratio vs. Peers

How is INVA’s Current Ratio compared to its peers?

Innoviva, Inc.’s Current Ratio is greater than eFFECTOR Therapeutics, Inc. (1.03), less than Protalix BioTherapeutics, Inc. (1.98), greater than PDS Biotechnology Corporation (0.00), less than aTyr Pharma, Inc. (6.07), less than Elevation Oncology, Inc. (17.77), less than Day One Biopharmaceuticals, Inc. (14.62), less than Mirati Therapeutics, Inc. (7.54), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Terns Pharmaceuticals, Inc. (32.99), less than Apellis Pharmaceuticals, Inc. (4.36), less than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than HOOKIPA Pharma Inc. (3.26), less than Acumen Pharmaceuticals, Inc. (10.43), less than Amicus Therapeutics, Inc. (3.15), less than Incyte Corporation (1.87), less than Denali Therapeutics Inc. (9.98), less than argenx SE (8.53), less than Harmony Biosciences Holdings, Inc. (3.24),

Build a custom stock screener for Innoviva, Inc. (INVA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Innoviva, Inc. (INVA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.